133
Participants
Start Date
January 16, 2014
Primary Completion Date
June 13, 2025
Study Completion Date
March 31, 2027
ATV
Capsules administered once daily according to dosing recommendations per product monograph
DRV
Tablets administered once daily according to dosing recommendations per product monograph
Cobicistat
Tablets administered orally once daily with food
BR
Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
F/TAF
Tablets administered orally once daily
LPV/r
Solution administered orally
Third Unboosted Drug
ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
Cobicistat TOS
Tablets for oral suspension
F/TAF TOS
Tablets for oral suspension
The Aurum Institute: Pretoria Clinical Research Centre, Pretoria
MU-JHU Research Collaboration/MU-JHU Care Ltd, Kampala
Hospital General de Agudos Cosme Argerich, Buenos Aires
Perinatal HIV Research Unit, Soweto
Rahima Clinical Trials, a Division of Wits Health Consortium (Pty) Ltd, Johannesburg
King Edward VIII Hospital, Durban
University of Stellenbosch, Cape Town
University of the Free State, Bloemfontein
HIV-NAT, Bangkok
Siriraj Hospital, Bangkok
The George Washington University, Washington D.C.
University of South Florida, Tampa
St. Jude Children's Research Hospital, Memphis
Srinagarind Hospital, Khon Kaen
University of Texas Health Science Center of Houston, Houston
University of Colorado Denver, Aurora
Peter Morton Medical Building, Los Angeles
Pediatric Infectious Disease Associates, Long Beach
Helios Salud, Buenos Aires
SICRA-TASO Mulago National Referral Hospital, Kampala
AMBSO Masaka Clinical Research Site, Masaka
University of Zimbabwe Clinical Research Centre, Harare
Imperial College Healthcare NHS Trust, London
Lead Sponsor
Gilead Sciences
INDUSTRY